Who is sponsoring NCT06145035?

NCT06145035 is sponsored by Roberto Bolli.

What drugs are being tested in NCT06145035?

Interventions in NCT06145035: umbilical cord-derived mesenchymal stromal cells (UC-MSCs).

What condition does NCT06145035 study?

NCT06145035 studies Ischemic Heart Disease.

Is NCT06145035 still recruiting?

NCT06145035 is currently recruiting now. Last updated 26 October 2024.

Last reviewed 2024-10-26 · How we verify

NCT06145035: CATO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

Recruiting now Phase 2 Last updated 26 October 2024

What this trial tests

Phase 2 trial testing umbilical cord-derived mesenchymal stromal cells (UC-MSCs) in Ischemic Heart Disease in 60 participants. Currently enrolling.

Timeline

4 March 2024

Primary endpoint
1 January 2026

1 January 2026

Quick facts

Lead sponsor	Roberto Bolli
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	4 March 2024
Primary completion	1 January 2026
Estimated completion	1 January 2026
Sites	3 locations across United States

Drugs / interventions tested

umbilical cord-derived mesenchymal stromal cells (UC-MSCs) — full drug profile →

Conditions studied

Ischemic Heart Disease — all drugs for Ischemic Heart Disease →

Sponsor

Roberto Bolli — full company profile →

Who can join

Adults 21 to 85, any sex, with Ischemic Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase IIA, randomized, double blind, placebo controlled, multicenter study designed to assess the safety, feasibility, and efficacy of umbilical cord derived mesenchymal stromal cells (UC MSCs), administered intravenously (IV) as a single dose or repeated doses, in patients with ischemic cardiomyopathy (ICM).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies.
Wang J, Zhang M, Wang H. · · 2024 · cited 13× · PMID 39144566 · DOI 10.1021/acsptsci.4c00284
Intravenous infusions of mesenchymal stromal cells have cumulative beneficial effects in a porcine model of chronic ischaemic cardiomyopathy.
Tang XL, Wysoczynski M, Gumpert AM, Solanki M, et al · · 2024 · cited 9× · PMID 39163570 · DOI 10.1093/cvr/cvae173
Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy.
Bolli R, Tang XL, Hare JM, Mitrani RD, et al · · 2026 · PMID 41397478 · DOI 10.1016/j.ahj.2025.107328

Verify or expand the search:

Other recruiting trials for Ischemic Heart Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT06712862 — A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR · recruiting
NCT07009418 — Smart Angioplasty Research Team-Coronary CT Angiography Versus Standard Care as Follow-up Strategies in High-Risk Patien · NA · recruiting
NCT06891456 — Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06145035 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roberto Bolli
Last refreshed: 26 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing